UK markets close in 3 hours 55 minutes

NVO Jan 2024 55.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.05000.0000 (0.00%)
As of 10:19AM EDT. Market open.
Full screen
Previous close2.0500
Open1.9000
Bid0.0000
Ask5.0000
Strike55.00
Expiry date2024-01-19
Day's range1.9000 - 2.0500
Contract rangeN/A
Volume4
Open interest2
  • Motley Fool

    This Big Pharma Stock Just Got an Upgrade. Is It Time to Buy?

    Shares of Eli Lilly (NYSE: LLY) recently ticked higher in response to encouraging words from a Wall Street analyst who follows the pharmaceutical industry. Colin Bristow at UBS, an investment bank, thinks this is the most attractive pharma stock you can buy right now. Is Bristow right about Eli Lilly?

  • Globe Newswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 26 September 2022 – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme

  • Globe Newswire

    More people with type 2 diabetes achieved blood sugar target with once-weekly insulin icodec compared with once-daily insulin degludec

    Data presented today show more participants achieved greater treatment satisfaction when switching to once-weekly insulin icodec in ONWARDS 2 trial Bagsværd, Denmark, Thursday 22 September 2022 – Novo Nordisk today presented new data from the phase 3a ONWARDS 2 trial, demonstrating that 37% of adults with type 2 diabetes treated with once-weekly insulin icodec achieved an HbA1c <7.0%, without experiencing severe or clinically significant hypoglycaemia, compared with 27% of those treated with ins